MX2016013434A - Inhibidores potentes y selectivos del virus de la hepatitis c. - Google Patents

Inhibidores potentes y selectivos del virus de la hepatitis c.

Info

Publication number
MX2016013434A
MX2016013434A MX2016013434A MX2016013434A MX2016013434A MX 2016013434 A MX2016013434 A MX 2016013434A MX 2016013434 A MX2016013434 A MX 2016013434A MX 2016013434 A MX2016013434 A MX 2016013434A MX 2016013434 A MX2016013434 A MX 2016013434A
Authority
MX
Mexico
Prior art keywords
virus
hepatitis
potent
selective inhibitors
compounds
Prior art date
Application number
MX2016013434A
Other languages
English (en)
Spanish (es)
Inventor
Junxing Shi
Steven J Coats
Richard Anthony Whitaker
Raymond F Schinazi
Amblard Franck
Rosario Mcbrayer Tamara
Zhang Hongwang
Zhou Longhu
Original Assignee
Cocrystal Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cocrystal Pharma Inc filed Critical Cocrystal Pharma Inc
Publication of MX2016013434A publication Critical patent/MX2016013434A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2016013434A 2014-04-15 2015-04-15 Inhibidores potentes y selectivos del virus de la hepatitis c. MX2016013434A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461980016P 2014-04-15 2014-04-15
PCT/US2015/025903 WO2015160907A2 (en) 2014-04-15 2015-04-15 Potent and selective inhibitors of hepatitis c virus

Publications (1)

Publication Number Publication Date
MX2016013434A true MX2016013434A (es) 2017-03-03

Family

ID=54324704

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016013434A MX2016013434A (es) 2014-04-15 2015-04-15 Inhibidores potentes y selectivos del virus de la hepatitis c.

Country Status (14)

Country Link
US (1) US9926295B2 (enExample)
EP (1) EP3131892A4 (enExample)
JP (1) JP2017513852A (enExample)
KR (1) KR20170002407A (enExample)
CN (1) CN106661004A (enExample)
AU (1) AU2015247706A1 (enExample)
BR (1) BR112016023833A2 (enExample)
CA (1) CA2945514A1 (enExample)
IL (1) IL248318A0 (enExample)
MX (1) MX2016013434A (enExample)
PH (1) PH12016502039A1 (enExample)
RU (1) RU2016144076A (enExample)
SG (1) SG11201608587QA (enExample)
WO (1) WO2015160907A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
JP2016527232A (ja) 2013-07-17 2016-09-08 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Hcvの治療に使用するためのビフェニル誘導体を含む組み合わせ
WO2015184644A1 (zh) * 2014-06-06 2015-12-10 爱博新药研发(上海)有限公司 抑制丙肝病毒的化合物、药物组合物及其应用
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN112203652A (zh) * 2018-05-09 2021-01-08 共晶制药公司 用于治疗hcv的组合疗法
CN109456375B (zh) * 2018-12-11 2019-10-22 枣庄学院 一种抑制丙肝病毒的含单糖基杂环类化合物及制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101492672B1 (ko) * 2008-02-13 2015-02-16 브리스톨-마이어스 스큅 컴퍼니 C형 간염 바이러스 억제제로서의 이미다졸릴 바이페닐 이미다졸
CA2751458C (en) * 2009-02-06 2018-06-05 Rfs Pharma, Llc Purine nucleoside monophosphate prodrugs for treatment of cancer and viral infections
US8377980B2 (en) * 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
BR112013004520A2 (pt) * 2010-08-26 2016-06-07 Univ Emory inibidores potentes e seletivos do virus da hepatite c
WO2012048421A1 (en) * 2010-10-14 2012-04-19 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
MX2013004906A (es) * 2010-11-01 2013-12-06 Genoscience Pharma Nuevos inhibidores especificos de la proteasa ns3 de hcv.

Also Published As

Publication number Publication date
SG11201608587QA (en) 2016-11-29
IL248318A0 (en) 2016-11-30
RU2016144076A (ru) 2018-05-16
KR20170002407A (ko) 2017-01-06
CA2945514A1 (en) 2015-10-22
JP2017513852A (ja) 2017-06-01
WO2015160907A2 (en) 2015-10-22
US20170029407A1 (en) 2017-02-02
EP3131892A2 (en) 2017-02-22
EP3131892A4 (en) 2017-09-20
BR112016023833A2 (pt) 2017-10-10
WO2015160907A3 (en) 2016-12-01
AU2015247706A1 (en) 2016-10-27
PH12016502039A1 (en) 2017-01-09
US9926295B2 (en) 2018-03-27
CN106661004A (zh) 2017-05-10

Similar Documents

Publication Publication Date Title
JOP20210109A1 (ar) مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
PH12018550150A1 (en) Elimination of hepatitis b virus with antiviral agents
WO2012027712A3 (en) Potent and selective inhibitors of hepatitis c virus
CY1122792T1 (el) Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου δαγκειου ιου
ZA201606320B (en) Human plasma kallikrein inhibitors
PH12018502077A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
NZ703064A (en) Inhibitors of hepatitis c virus
PH12018500576A1 (en) Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
UA117518C2 (uk) 6-конденсовані гетероарилдигідропіримідини для лікування та профілактики зараження вірусом гепатиту b
PH12018502015A1 (en) Substituted indole derivatives as dengue viral replication inhibitors
MX2018011786A (es) Derivados de compuestos de indol sustituidos como inhibidores de la replicacion virica del dengue.
EA201892216A1 (ru) Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
EA201790700A1 (ru) Моно- или дизамещенные индолы в качестве ингибиторов репликации вирусов денге
NZ733313A (en) Indole derivatives as dengue viral replication inhibitors
PH12016502039A1 (en) Potent and selective inhibitors of hepatitis c virus
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
MY185672A (en) Mono-or di-substituted indole derivatives as dengue viral replication inhibitors
MY197383A (en) Mono- or di-substituted indole derivatives as dengue viral replication inhibitors